AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already know how to do.

Yet the value of AI tools that help biopharma do its job faster risks getting obscured by the persistent cloud of hype surrounding the space, which conflates the technology’s immediate potential to increase efficiency with its still unrealized ambitions to change failure rates in drug development by accessing insights humans can’t find on their own...